Frequently Asked Questions
The market is segmented based on Global Alzheimer's Disease Diagnostic Market, By Type (Nervous System, Examination, Genetic Testing, Minor Mental State Examination, and Brain Imaging), Diagnostic Test (Genetic Testing, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Other Diagnostics, Neurological Exam, and Mini-mental State Exam (MMSE), Brain Imaging, and Others), End Users (Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, and Academic Research Center) - Industry Trends and Forecast to 2030.
.
The Global Alzheimers Disease Diagnostic Market size was valued at USD 10376.30 USD Million in 2022.
The Global Alzheimers Disease Diagnostic Market is projected to grow at a CAGR of 9.4% during the forecast period of 2023 to 2030.
The major players operating in the market include AbbVie, AC Immune, AMARANTUS BIOSCIENCE HOLDINGS, Anavex Life Sciences Corp., Eli Lilly and Company, AXON Neuroscience, Sio Gene Therapies, Daiichi Sankyo Company, F. Hoffmann La Roche, General Electric Company, Janssen Pharmaceuticals, TauRx Pharmaceuticals Ltd, Alector , Accera , Treventis Corporation, NeuroBio, Cognition Therapeutics , Johnson & Johnson Services , Quanterix.
The market report covers data from the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)..
